Eli Lilly's orforglipron outperformed semaglutide in lowering blood sugar and weight in type 2 diabetes patients, with a U.S. decision expected in Q2 2026.

Eli Lilly’s oral GLP-1 drug orforglipron outperformed oral semaglutide in a Phase 3 trial, reducing A1C by 2.2% and causing an average 19.7 lb weight loss—73.6% greater than semaglutide—over 52 weeks in adults with type 2 diabetes. The drug, taken once daily without food restrictions, also improved cardiovascular risk factors. Though more effective, orforglipron had higher discontinuation rates due to gastrointestinal side effects. Lilly has submitted it for regulatory review in over 40 countries, with a U.S. decision expected in the second quarter of 2026.